Pharmafile Logo

addiction

Gilead Sciences

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share

- PMLiVE

Creating an engaging experience for patients

The patient experience is inextricably connected to how HCPs feel about their work and are measured and perceived, and that experience is no longer limited to the 15-minute office visit....

- PMLiVE

Stronger together

A patient-focused strategy is high on the agenda, with a top-down approach favoured by industry leaders

- PMLiVE

Celgene creates art gallery to highlight impact of psoriasis

Life's an Itch gallery will be used at meetings and medical conferences

- PMLiVE

Magic Eyes

How patient art can generate broader insights

Celgene building

Celgene: Patient voice often underrepresented in pricing debates

Dr Jackie Fouse says in the interests of transparency patients should be more involved

- PMLiVE

Gilead boosts liver disease pipeline with $1.2bn acquisition

Also has combination HIV therapy Descovy approved by FDA

- PMLiVE

Wearables – the technologist’s view

Patient insight is key to a successful solution

- PMLiVE

Harnessing the power of ethnography in healthcare

Locating the elusive, yet vital, insights into how people manage and live with their medical conditions

- PMLiVE

Changing behaviour by design

Are we underestimating the power of design in encouraging behaviours for the good of our health?

Infographic: HCV EU

Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...

Research Partnership

- PMLiVE

Avoiding an Authenticity Gap in healthcare communications

Successful companies align their brand with their reputation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links